Browsing by Author "Yumuk, Perran Fulden"

Now showing 1 - 7 of 7

Assesment of palliative care in lung cancer in Turkey (ASPECT study)
(European Respiratory Society, 2015-09-01) Bülbül, Yılmaz; Özlü, Tevfik; Arınç, Sibel; Özyürek, Berna A.; Günbatar, Hülya; Şentürk, Ayşegül; Bahadır, Ayşe; Özçelik, Melike; Yılmaz, Ufuk; Akbay, Makbule Özlem; Sağlam, Leyla; Kılıç, Talat; Kırkıl, Gamze; Özçelik, Neslihan; Tatar, Dursun; Barış, Serap Argun; Yavşan, Mehmet; Şen, Hatice Selimoğlu; Berk, Serdar; Acat, Murat; Çakmak, Gülfidan; Yumuk, Perran Fulden; İntepe, Yavuz Selim; Toru, Umran; Ayık, Sibel O.; Başyiğit, İlknur; Özkurt, Sibel; Mutlu, Levent Cem; Yaşar, Zehra Aşuk; Esme, Hıdır; Erol, Muharrem; Oruç, Özlem; Erdoğan, Yurdanur; Asker, Selvi; Ulaş, Arife; Erol, Serhat; Kerget, Buğra; Erbaycu, Ahmet Emin; Teke, Turgut; Beşiroğlu, Mehmet; Can, Hüseyin; Talay, Fahrettin; EROL, MUHARREM; JEN-3243-2023
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
(Springer, 2013-07) Korkmaz, Taner; Seber, Selçuk; Kefeli, Umut; Sarı, Enes; Öven, Bala Başak; Yıldırım, Emre; Yaşar, Nurgül; Balvan, Özlem; Şener, Nur Dinç ; Yüksel, Sinemis; Güven, Aslıhan Mert; Polat, Özge; Yumuk, Perran Fulden; Gümüş, Mahmut; Turhal, Nazım Serdar; Canhoroz, Mustafa; Aydın, Dinçer; Kanat, Özkan; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; CJW-6018-2022; CCE-1550-2022; CYM-0930-2022; 52663246200; 55438191100; 55881548500
Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods: We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion: Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.
(Lippincott Williams & Wilkins, 2011-05-20) Korkmaz, Taner; Seber, S.; Bilici, Ahmet; Okutur, Kerem; Toptaş, Tayfun; Başaran, Gül Atalay; Dede, Fuat; Yumuk, Perran Fulden; Dane, Faysal; Kanitez, Metin; Kanat, Oe; Gümüş, Mahmut; Demir, Gökhan; Turhal, Nazım Serdar; Canhoroz, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.
Efficacy and safety of trastuzumab emtansine in her2 positive metastatic breast cancer: Real-world experience
(Taylor & Francis, 2021-06-05) Bahçeci, Aykut; Paydaş, Semra; Ak, Naziye; Ferhatoğlu, Ferhat; Saip, Pınar Mualla; Şeydaoğlu, Gülşah; Bilici, Mehmet; Şimşek, Melih; Tekin, Salim Başol; Çalıkuşu, Züleyha; Yavuz, Sinan; Şahin, Ahmet Bilgehan; Çubukcu, Erdem; Evrensel, Türkkan; Değirmencioğlu, Serkan; Demiray, Atike Gökçen; Yumuk, Perran Fulden; Alan, Özkan; Çıkman, Duygu İlke; Demirelli, Fuat Hulusi; Köstek, Osman; Gökyer, Ali; Doğan, Mutlu; Bal, Öznur; Çakar, Burcu; Gökmen, Erhan; Yamaç, Deniz; Korkmaz, Taner; Aliyev, Altay; Keskin, Özge; Urvay, Semiha; Buyukşimşek, Mahmut; Karadeniz, Cemile; Yıldız, Birol; Çınkır, Havva Yeşil; Demir, Hacer; Beypınar, İsmail; Karacin, Cengiz; Eser, Kadir; Baykara, Meltem; Kılıçkap, Saadettin; Okutur, Kerem; Bulut, Gülcan; Alkan, Ali; Arpacı, Erkan; Pilancı, Kezban Nur; Demir, Atakan; Işık, Deniz; Yıldırım, Nilgün; ŞAHİN, AHMET BİLGEHAN; ÇUBUKÇU, ERDEM; EVRENSEL, TÜRKKAN; 0000-0002-7846-0870 ; AAM-4927-2020; JGT-4101-2023 ; EXZ-0745-2022
Aim The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey. Findings Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3-4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%). Discussion The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.
General characteristics and therapeutic options in lung cancer in Turkey
(European Respiratory, 2015-09-01) Özlü, Tevfik; Bülbül, Yılmaz; Arınç, Sibel; Özyürek, Berna A.; Günbatar, Hülya; Şenturk, Ayşegül; Bahadır, Ayşe; Özçelik, Melike; Yılmaz, Ufuk; Akbay, Makbule Özlem; Sağlam, Leyla; Kılıç, Talat; Kırkıl, Gamze; Özçelik, Neslihan; Tatar, Dursun; Barış, Serap Argun; Yavsan, Mehmet; Şen, Hatice Selimoğlu; Berk, Serdar; Acat, Murat; Çakmak, Gülfidan; Yumuk, Perran Fulden; İntepe, Yavuz Selim; Toru, Umran; Ayık, Sibel O.; Başyigit, İlknur; özkurt, Sibel; Mutlu, Levent Cem; Yaşar, Zehra Asuk; Esme, Hıdır; Erol, Muharrem; Oruç, Özlem; Erdogan, Yurdanur; Asker, Selvi; Ulaş, Arife; Erol, Serhat; Kerget, Bugra; Erbaycu, Ahmet Emin; Teke, Turgut; Beşiroğlu, Mehmet; Can, Hüseyin; Talay, Fahrettin; Erol, Muharrem; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Bölümü; JEN-3243-2023
Lung cancer in Turkey
(Elsevier Science Inc, 2022-10-01) Cangir, Ayten Kayi; Yumuk, Perran Fulden; Sak, Serpil Dizbay; Akyürek, Serap; Eralp, Yesim; Yılmaz, Ulku; Selek, Uğur; Eroglu, Atilla; Tatlı, Ali Murat; Dinçbaş, Fazilet Öner; Kılıçkap, Saadettin; Sendur, Mehmet Ali Nahit; Bozcuk, Hakan Sat; Özkök, Serdar; Öztop, İlhan; Topkan, Erkan; Dilege, Sükrü; Kaya, Akın; Demirkazık, Ahmet; Dilektasli, Asli Gorek; GÖREK DİLEKTAŞLI, ASLI; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.
Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: The single-arm, open-label regard study
(BMJ Publishing Group, 2020-03) Dane, Faysal; Özgürdal, Kırhan; Yalçın, Şuayib; Benekli, Mustafa; Aykan, Nuri Faruk; Yücel, İdris; Özkan, Metin; Sevinç, Alper; Coşkun, Hasan Şenol; Şanlı, Ulus Ali; Kara, İsmail Oğuz; Yumuk, Perran Fulden; Evrensel, Türkkan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; 6603942124
Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC. Design Open-label, single-arm, phase IIIb study conducted between July 2013 and April 2015. Setting 11 tertiary centres in Turkey. Participants Eligible patients were adults with mCRC who had disease progression within 3 months after receiving their last dose of approved standard therapies and who had an Eastern Cooperative Oncology Group performance status <= 1. Patients were excluded if they had previously received regorafenib. Of 139 patients screened, 100 were treated and completed the study, and all 100 were analysed. Fifty-eight per cent were male. Interventions Patients received oral regorafenib, 160 mg once daily, for the first 3 weeks of each 4-week cycle until disease progression, death or unacceptable toxicity. Primary and secondary outcome measures The primary endpoint was safety, assessed by incidence of treatment-emergent adverse events (TEAEs). Progression-free survival (PFS) per investigator was the primary efficacy endpoint. There were no secondary endpoints. Results The median treatment duration was 2.5 months (range 0.1 to 20.6). Ninety-six per cent of patients had at least one TEAE and 77% had a grade >= 3 TEAE. The most common grade >= 3 regorafenib-related TEAEs were hypophosphataemia (11%), fatigue (8%), hyperbilirubinaemia (6%), hand-foot skin reaction (5%), hypertension (5%), anorexia (5%) and increased alanine aminotransferase (5%). TEAEs led to dose reduction in 30% of patients. Regorafenib-related TEAEs led to treatment discontinuation in 17% of patients. Median PFS was 3.1 months (95% CI 2.9 to 3.8). Conclusion The regorafenib safety profile and PFS in REGARD were consistent with the results of previous trials of regorafenib in mCRC. Regorafenib is an option for patients in Turkey with treatment-refractory mCRC.